Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program Precision BioSciences, Inc. a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for…
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors Parabilis Medicines, a clinical-stage biopharmaceutical…
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan Curatis Holding AG and Neupharma Co., Ltd. a…
TIXiMED Reports Promising Preclinical Results for Oral TIX100 in Preventing Weight Regain After GLP-1 Therapy TIXiMED a clinical-stage pharmaceutical company focused on developing innovative treatments for diabetes and metabolic diseases,…
Verasonics Announces Vantage® NXT Platform Update Featuring Encoder Integration, Focused Ultrasound 2D/3D Software, New 8 MHz Matrix Array Transducer Verasonics, Inc., the leader in research ultrasound, announced the release of a significant…
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C GeneDx the leader in rare disease diagnosis and improving health through the…
QT Imaging Receives FDA Clearance for Its Breast Acoustic CT Scanner Enhanced Configuration to Improve Posterior Breast Imaging Coverage QT Imaging Holdings, Inc. a medical device company dedicated to transforming…
Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™ Butterfly Network, Inc. a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, announced…
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy Vertex Pharmaceuticals Incorporated…
First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy Emalex Biosciences today announced that the first patient was dosed in its Expanded Access Program for…
Obesity Drug Olatorepatide, Licensed by Regeneron Pharmaceuticals, Shows Positive Phase 3 Outcomes in Chinese Patients Regeneron Pharmaceuticals, Inc. today announced Hansoh Pharmaceutical Group Company Limited has shared positive topline data from its…
Bristol Myers Squibb Reports Positive Phase 3 SUCCESSOR-2 Trial Results for Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma Bristol Myers Squibb (NYSE: BMY) today announced positive interim Phase 3 results…
